1. Home
  2. CRBU

as 08-28-2025 9:37am EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Founded: 2011 Country:
United States
United States
Employees: N/A City: BERKELEY
Market Cap: 188.8M IPO Year: 2021
Target Price: $6.67 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.79 EPS Growth: N/A
52 Week Low/High: $0.66 - $3.00 Next Earning Date: 08-12-2025
Revenue: $9,121,000 Revenue Growth: -72.45%
Revenue Growth (this year): 9.23% Revenue Growth (next year): -3.23%

CRBU Daily Stock ML Predictions

Share on Social Networks: